Results 171 to 180 of about 5,447,906 (320)
Trends in Lower Limb Orthoplastic Surgery: A Bibliometric Analysis. [PDF]
Bompolas P +5 more
europepmc +1 more source
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Broadband high-resolution X-ray ptychography system spanning tender to hard X-ray regimes. [PDF]
Sasaki Y +7 more
europepmc +1 more source
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
De-coherent parallel laser processing of ultradense nanopores for high-density, large-area 3D optical phase encoding. [PDF]
Jiang Z +6 more
europepmc +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Automatic Weld Defect Detection in Steel Plates Based on Ultrasonic Total Focusing Method and Multi-layer Feature Fusion Target Detection Network [PDF]
QIN Feihong +5 more
openalex +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

